MX2021009508A - Metodo para la administracion segura de una vacuna de peptido de tau fosforilado. - Google Patents

Metodo para la administracion segura de una vacuna de peptido de tau fosforilado.

Info

Publication number
MX2021009508A
MX2021009508A MX2021009508A MX2021009508A MX2021009508A MX 2021009508 A MX2021009508 A MX 2021009508A MX 2021009508 A MX2021009508 A MX 2021009508A MX 2021009508 A MX2021009508 A MX 2021009508A MX 2021009508 A MX2021009508 A MX 2021009508A
Authority
MX
Mexico
Prior art keywords
phosphorylated tau
peptide vaccine
tau peptide
safe administration
methods
Prior art date
Application number
MX2021009508A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Muhs
Andrea Pfeifer
Elizabeth Anne Ramsburg
Marco Donata De
Charlotte Sadaka
Verhille Marija Vukicevic
Nicolas Piot
Saroj Raj Ghimire
Bosch Maria Pihlgren
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2021009508A publication Critical patent/MX2021009508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021009508A 2019-02-08 2020-02-07 Metodo para la administracion segura de una vacuna de peptido de tau fosforilado. MX2021009508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802870P 2019-02-08 2019-02-08
PCT/US2020/017235 WO2020163730A2 (en) 2019-02-08 2020-02-07 Method of safe administration of phosphorylated tau peptide vaccine

Publications (1)

Publication Number Publication Date
MX2021009508A true MX2021009508A (es) 2021-09-08

Family

ID=69780323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009508A MX2021009508A (es) 2019-02-08 2020-02-07 Metodo para la administracion segura de una vacuna de peptido de tau fosforilado.

Country Status (17)

Country Link
US (3) US11684576B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920966A2 (cg-RX-API-DMAC7.html)
JP (2) JP7541527B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210125048A (cg-RX-API-DMAC7.html)
CN (1) CN113710269A (cg-RX-API-DMAC7.html)
AU (1) AU2020219804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014794A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129252A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192203A1 (cg-RX-API-DMAC7.html)
IL (1) IL285163B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210211A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009508A (cg-RX-API-DMAC7.html)
MY (1) MY206596A (cg-RX-API-DMAC7.html)
PH (1) PH12021551876A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108312PA (cg-RX-API-DMAC7.html)
TW (1) TWI868106B (cg-RX-API-DMAC7.html)
WO (1) WO2020163730A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN114728169A (zh) * 2019-09-23 2022-07-08 麦考瑞大学 tau蛋白病的治疗
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
KR20240042508A (ko) * 2021-08-12 2024-04-02 얀센 파마슈티칼즈, 인코포레이티드 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜
US20250134991A1 (en) * 2021-08-20 2025-05-01 Thomas Jefferson University Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
EA003739B1 (ru) 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
AU2003203079B9 (en) 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
KR100994748B1 (ko) * 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
WO2005058137A2 (en) 2003-12-12 2005-06-30 University Of Washington Catheterscope 3d guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2006121656A2 (en) 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
MX2011009654A (es) 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2811188C (en) 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
WO2013058350A1 (ja) 2011-10-21 2013-04-25 三菱化学株式会社 周期表第13族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第13族金属窒化物半導体結晶
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP4657376A3 (en) 2015-08-14 2026-03-04 Intuitive Surgical Operations, Inc. Systems and methods of registration for image-guided surgery
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.

Also Published As

Publication number Publication date
CN113710269A (zh) 2021-11-26
US12324855B2 (en) 2025-06-10
PH12021551876A1 (en) 2022-05-23
US20230381108A1 (en) 2023-11-30
IL285163B2 (en) 2025-05-01
BR112021014794A2 (pt) 2021-10-05
AU2020219804A1 (en) 2021-08-19
IL285163A (en) 2021-09-30
SG11202108312PA (en) 2021-08-30
US11684576B2 (en) 2023-06-27
IL285163B1 (en) 2025-01-01
TWI868106B (zh) 2025-01-01
US20200253873A1 (en) 2020-08-13
JP2024178161A (ja) 2024-12-24
JOP20210211A1 (ar) 2023-01-30
JP7541527B2 (ja) 2024-08-28
JP2022520060A (ja) 2022-03-28
EP3920966A2 (en) 2021-12-15
US20250275920A1 (en) 2025-09-04
KR20210125048A (ko) 2021-10-15
CA3129252A1 (en) 2020-08-13
EA202192203A1 (ru) 2021-10-20
MY206596A (en) 2024-12-25
TW202045204A (zh) 2020-12-16
WO2020163730A3 (en) 2020-09-24
WO2020163730A2 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MY206596A (en) Method of safe administration of phosphorylated tau peptide vaccine
IL283840A (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
MX2021012994A (es) Administracion heterologa de vacunas tau.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2025002686A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo
BR112021019558A2 (pt) Composições e métodos para preparar composições de células t e usos dos mesmos
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2020005166A (es) Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
CR20210373A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
CL2015001923A1 (es) Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
Kobiyama et al. A clinically applicable adjuvant for an atherosclerosis vaccine in mice
CL2021002401A1 (es) Extractos bacterianos estables como fármacos
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
PH12020551670A1 (en) Anti-abeta therapeutic vaccines
CO2022017087A2 (es) Péptidos y métodos para el tratamiento de esclerosis múltiple
MX2018015108A (es) Metodos para tratar la osificacion heterotopica.
CL2021003051A1 (es) Terapia de vacuna anti-abeta.
MX2021009662A (es) Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.